ACTDrug® + : Seizes Opportunities In Late-Stage Treatment
In the medical journey of cancer treatment, precision medicine is recognized as a modern and favored way for healthcare system to take care of cancer patients more easily. Challenges of identifying the right drug to every cancer patient while new drugs are emerging for specific genomic mutations can be tackled strategically by having cancer patients’ unique cancer genomic profiles. The acceleration of oncology drug approvals and the modernization of clinical trials with biomarker-based patients have progressed well as USFDA committed from 2018. The wave of precision medicine also increases approvals of companion diagnostics, bringing ACT Genomics’ genomic profiling service on the waiting list of USFDA approval.
Why You Need To Know About Precision Medicine
Top global pharma companies fasten the pace to conduct clinical trials of precision medicine, which requires cancer patients’ genomic information via genomic profiling.This evolution affects most hospitals, so you need to get prepared for the genomic profiling if you are always looking for a new treatment.
When it comes to a big decision in life, you can’t be careful enough, including your targeted therapy. There are often more than one target in tumor, and if you shoot them with a strategy rather than one guesswork after another can often make tumor into controlled, while most people don’t realize the difference and lose the chance in the beginning. Cancer genomic profiling enables major targets to be revealed all at once such as EGFR, ALK, ROS1…etc, and by identifying the driver gene, you can target at the bull's eye and increase chance of having a successful treatment.
? Chemotherapy and surgery are the only options according to NCCN guideline or single gene test result
? Complicated and metastases, hard to know the appropriate drugs
? Ineffective treatment, and cancer relapse after targeted therapy
? Pursue for immunotherapy, targeted therapy and wondering the effect
Diagnostic Solutions For Various Cancers
Through Next Generation Sequencing (NGS), ACTDrug® + targeted genomic profiling decodes 40 cancer genes to map drug options via many clinical researches, not limit to single clinical treatment guideline and controls the growth mechanism from genomic level to enable more treatment strategy with higher success rate.
Suitable for breast, lung, colon cancer and other solid tumors. If single gene test does not bring satisfying result, NGS genomic profiling can detect special genomic mutations for better treatment; if recurrence or metastases is found, treatment can be modified according to NGS genomic profiling result to overcome drug resistance.
Targeted Genomic Profiling Can Bring Treatment Advantages As Follows:
? More humanized process : Avoid multiple biopsies and time cost of single gene test, few specimen required for various fusion gene detection at once.
? More ideal treatment : Find proper targeted options
? Plan medical budget more intelligently : Evaluate options before treatment according to genomic information, to ensure success rate and avoid waste of medical budget.
Listen To The Successful Fighters' StoriesMany cancer patients are diagnosed late stage, and some patients will know precision medicine is because they have medical background or being recommended by physicians. Listen to their stories and help them bring hope to more people.
Cancer Patient Stories :
? Who Can Use: Patients with lung cancer or other sollid tumors
? Specimen Type : Tumor sample
? Tournaround Time :
ACTDrug® : 8 working days after qualified specimen recieved
ACTFusion™ : 10 working days after qualified specimen recieved